Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
In a significant move for the international scientific community, the leadership of Cornell University has forcefully reaffirmed its commitment to the Jacobs Technion-Cornell Institute, rejecting recent student-led calls to sever ties with the Technion – Israel Institute of Technology. The decision marks a pivotal moment
Hope for patients suffering from severe tissue damage: Technion researchers have developed an implantable tissue flap containing muscle and fat tissues alongside a hierarchical network of blood vessels and lymphatic vessels.
Deciding whether to administer chemotherapy after surgery is one of the most challenging questions in early‑stage breast cancer care. While chemotherapy can reduce the risk of recurrence, most patients do not benefit from it and may experience significant short‑ and long‑term side effects. The central challenge is identifying, at the time of diagnosis, which patients are likely to benefit, and which are not.
